Skip to main
GLSI
GLSI logo

Greenwich Lifesciences (GLSI) Stock Forecast & Price Target

Greenwich Lifesciences (GLSI) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Greenwich LifeSciences Inc. has reported promising immune response data from its Phase III FLAMINGO-01 trial of GLSI-100, indicating a positive trend in immune responses among patients throughout the vaccination period. The encouraging preliminary results suggest the potential for substantial patient eligibility, potentially doubling the target population to around 88,000 new patients annually in the U.S. Additionally, the ongoing expansion of Flamingo-01 into Europe, with plans for up to 150 global sites, could enhance the company’s market reach and overall growth prospects.

Bears say

Greenwich LifeSciences Inc. reported a net loss of $15.8 million, amounting to $1.21 per share, indicating substantial financial challenges as the company advances its Phase III clinical trial, Flamingo-01. The outlook is further complicated by significant risks including the potential failure of the GP2 immunotherapy in clinical trials, difficulties in obtaining regulatory approval, and the possibility of unmet commercial success due to market size, penetration rates, and competition. Additionally, there is a concern regarding dilution risk, which could exacerbate the financial instability and negatively impact shareholder value.

Greenwich Lifesciences (GLSI) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Greenwich Lifesciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Greenwich Lifesciences (GLSI) Forecast

Analysts have given Greenwich Lifesciences (GLSI) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Greenwich Lifesciences (GLSI) has a Strong Buy consensus rating as of Oct 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $39, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $39, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Greenwich Lifesciences (GLSI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.